The DOI matches its Crossref record.
Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats
Abstract
The present study was undertaken to determine the effect of pioglitazone (3, 10 and 30 mg/kg p.o.), an insulin sensitizer, on glucose intolerance in high fat diet- (HFD) fed rats (a nongenetic model of insulin resistance). In addition, the effect of pioglitazone (3, 10 and 30 mg/kg p.o.) on diet-induced changes in body weight, plasma glucose, insulin, triglyceride and total cholesterol levels were also determined. The feeding of HFD for 4 weeks produced a significant increase in body weight, total fat pad weight, basal/fasting plasma glucose, insulin, basal triglyceride (TG) and total cholesterol (TC) levels in male rats. Furthermore, the rats fed HFD exhibited fasting hyperglycemia and hyperinsulinemia as well as enhanced glycemic response to exogenously administered glucose (2 g/kg p.o.) during an oral glucose tolerance test (OGTT) at the end of 4 weeks of dietary manipulation, indicating that the rats had developed insulin resistance and glucose intolerance. Treatment with pioglitazone (10 and 30 mg/kg p.o.) once daily for 2 weeks significantly diminished the elevated basal plasma insulin and TG levels in HFD-fed rats. In addition, a statistically significant reduction in TC level was observed only with the high dose of pioglitazone (30 mg/kg p.o.). However, pioglitazone had no significant effect on body weight, total fat pad weight and basal plasma glucose level. Pioglitazone (10 and 30 mg/kg p.o.) significantly reduced fasting hyperglycemia and reversed oral glucose intolerance to normal in HFD-fed rats compared with control normal rats. The above findings suggest that pioglitazone has potent insulin-sensitizing and lipid-lowering properties in a HFD-fed rat model. In conclusion, the present study demonstrates that the adult male rats on a HFD for 4 weeks exhibited the characteristic features of obesity, insulin resistance and glucose intolerance, namely increased body weight, increased total fat pad weight, mild basal/fasting hyperglycemia, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia and impaired oral glucose tolerance, that closely resemble the human prediabetic obese insulin-resistant and glucose-intolerant state. Further treatment with pioglitazone once daily for 2 weeks significantly ameliorated changes in basal plasma insulin, TG and TC, and reversed oral glucose intolerance to normal in HFD-fed rats, suggesting its potential in the treatment of insulin resistance and glucose intolerance associated with abnormal lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C. L., & Ramarao, P. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.05.004 · Cited by 1,874
Self-citationTargeting Inflammation-Induced Obesity and Metabolic Diseases by Curcumin and Other Nutraceuticals
Aggarwal, B. B. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104755 · Cited by 471
Eleazu, C. O., Eleazu, K. C., Chukwuma, S., & Essien, U. N. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-60 · Cited by 459
Focal adhesion kinase regulates insulin resistance in skeletal muscle
Bisht, B., Goel, H. L., & Dey, C. S. (2007) · Diabetologia · doi:10.1007/s00125-007-0591-6 · Cited by 63
Metadata
- Authors
- Srinivasan, K., Patole, P. S., Kaul, C. L., & Ramarao, P.
- Venue
- Methods and Findings in Experimental and Clinical Pharmacology
- Publisher
- Portico
- Published
- 2004
- Volume
- 26
- Issue
- 5
- Pages
- 327
- ISSN
- 0379-0355 (ISSN-L)
- 2013-0155
- OpenAlex
- W2033522292
- Cited by
- 186
- References
- 0
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats. https://app.cochat.ai/papers/10.1358/mf.2004.26.5.831322
- The paper
- Srinivasan, K., Patole, P. S., Kaul, C. L., & Ramarao, P. (2004). Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats. Methods and Findings in Experimental and Clinical Pharmacology. https://doi.org/10.1358/mf.2004.26.5.831322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.